Independent advisors for the Food and Drug Administration (FDA) have voted unanimously in favor of approving Moderna’s seasonal mRNA flu vaccine, following a contentious review process that saw attempts to block its evaluation. The vote, which concluded with a 9-0 outcome, took place during an all-day meeting of the FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC).
The meeting featured comprehensive analyses, presentations, and discussions centered on the vaccine, officially named mRNA-1010 and branded as mFlusiva. Among the data reviewed was a supportive report from FDA scientists, which highlighted the promising effectiveness of the new vaccine format.
Recent Phase 3 trial data involving more than 40,000 adults aged 50 and older indicated that Moderna’s mRNA vaccine was approximately 27 percent more effective at preventing seasonal flu compared to traditional flu shots. Furthermore, a separate Phase 3 trial that included nearly 3,000 participants aged 65 years and older demonstrated that the vaccine elicited stronger immune responses than the high-dose flu vaccine typically recommended for this demographic. The overall safety profile of mFlusiva was also deemed satisfactory by the committee.
Following the vote, Flor Munoz-Rivas, a pediatric infectious disease expert at Baylor College of Medicine and a voting member of the committee, remarked on the quality and clarity of the studies presented. She noted the compelling evidence that underscored the vaccine’s efficacy and expressed optimism regarding the mRNA technology used in its development. Munoz-Rivas emphasized that this platform not only enhances the vaccine’s effectiveness but also facilitates rapid vaccine development in response to seasonal flu variations, thereby improving preparedness for future emerging strains and potential pandemics.
The endorsement from VRBPAC could signal a significant advance in the fight against seasonal flu, as the agility of the mRNA platform offers a modern approach to vaccine development that mirrors the successful application seen in COVID-19 vaccine production.
